Literature DB >> 10866826

Analysis of CAK activities from human cells.

P Kaldis1, M J Solomon.   

Abstract

The cdk-activating kinase (CAK) activates cyclin-dependent kinases (cdks) that control cell-cycle progression by phosphorylating a threonine residue conserved in cdks. CAK from humans contains p40MO15 (cdk7), cyclin H and MAT1, which are also subunits of transcription factor IIH where they phosphorylate the C-terminal domain of the large subunit of RNA polymerase II. In contrast, budding yeast Cak1p is a monomeric enzyme without C-terminal domain kinase activity. Here, we analyze CAK activities in HeLa cells using cdk2-affinity chromatography. In addition to MO15, a second CAK activity was detected that runs on gel filtration at 30-40 kDa. This activity phosphorylated and activated cdk2 and cdk6. Furthermore, this 'small CAK' activity resembled Cak1p rather than MO15 in terms of substrate specificity, reactivity to antibodies against MO15 and Cak1p, and sensitivity to 5'-fluorosulfonylbenzoyladenosine, an irreversible inhibitory ATP analog. Our findings suggest the presence of at least two different CAK activities in human cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866826     DOI: 10.1046/j.1432-1327.2000.01455.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  19 in total

1.  Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.

Authors:  Stéphane Larochelle; Karl A Merrick; Marie-Emilie Terret; Lara Wohlbold; Nora M Barboza; Chao Zhang; Kevan M Shokat; Prasad V Jallepalli; Robert P Fisher
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

Review 2.  Cytokine signaling to the cell cycle.

Authors:  Frederick W Quelle
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors".

Authors:  Laurence Bockstaele; Hugues Kooken; Frederick Libert; Sabine Paternot; Jacques E Dumont; Yvan de Launoit; Pierre P Roger; Katia Coulonval
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

4.  Specificity of Cdk activation in vivo by the two Caks Mcs6 and Csk1 in fission yeast.

Authors:  D Hermand; T Westerling; A Pihlak; J Y Thuret; T Vallenius; M Tiainen; J Vandenhaute; G Cottarel; C Mann; T P Mäkelä
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

5.  Positive and negative regulation of c-Myb by cyclin D1, cyclin-dependent kinases, and p27 Kip1.

Authors:  Wanli Lei; Fan Liu; Scott A Ness
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

6.  Dna damage-induced G(1) arrest in hematopoietic cells is overridden following phosphatidylinositol 3-kinase-dependent activation of cyclin-dependent kinase 2.

Authors:  A K Eapen; M K Henry; D E Quelle; F W Quelle
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

7.  Identification of yin-yang regulators and a phosphorylation consensus for male germ cell-associated kinase (MAK)-related kinase.

Authors:  Zheng Fu; Katherine A Larson; Raghu K Chitta; Sirlester A Parker; Benjamin E Turk; Matthew W Lawrence; Philipp Kaldis; Konstantin Galaktionov; Steven M Cohn; Jeffrey Shabanowitz; Donald F Hunt; Thomas W Sturgill
Journal:  Mol Cell Biol       Date:  2006-09-05       Impact factor: 4.272

8.  Cell cycle-related kinase in carcinogenesis.

Authors:  Ye Tian; Han Wan; Guang Tan
Journal:  Oncol Lett       Date:  2012-07-27       Impact factor: 2.967

9.  Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.

Authors:  Laurence Bockstaele; Xavier Bisteau; Sabine Paternot; Pierre P Roger
Journal:  Mol Cell Biol       Date:  2009-06-01       Impact factor: 4.272

10.  Over expression of Plk1 does not induce cell division in rat cardiac myocytes in vitro.

Authors:  Carmen H Coxon; Katrina A Bicknell; Fleur L Moseley; Gavin Brooks
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.